Chelsea Therapeutics is committed to developing novel therapeutic agents that address disease states that correspond to significant unmet medical need. Chelsea received FDA accelerated approval for NORTHERA™ (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) in adult patients. NORTHERA is the first and only therapy approved by the FDA to address specific underlying symptoms of Symptomatic NOH. For more information on NORTHERA visit our Products page.
Our pipeline also includes a library of metabolically inert antifolate medications, including a clinical-stage product, CH-4051, for the treatment of rheumatoid arthritis and other autoimmune diseases.
OUR R&D PIPELINE
|Compound||Indication||Phase I||Phase II||Phase III||NDA Submitted|
|Droxidopa (Northera™)||Symptomatic Neurogenic Orthostatic Hypotension|